Ripple Therapeutics Announces First Patient Treated in Phase II Trial Evaluating IBE-814 IVT in DME and RVO
Sheardown Lab and Ripple Therapeutics receive NSERC grant to improve treatment for millions with eye disease
Ripple Therapeutics pursues financing for Phase 2 intravitreal implant trial and Epidel platform expansion
Pharmacokinetics and Pharmacodynamics of a Novel Dexamethasone Intravitreal Implant IBI Abstract Presented at ARVO 2019
IBI Poster at AUA 2019: In vitro evaluation of novel surface modifying molecules to prevent bacterial adhesion to urological devices
Fresenius Medical Care Receives FDA Breakthrough Device Designation for New Dialysis System to Prevent Blood Clotting Without the Use of Blood Thinners
